Blood and Bone Marrow Stem Cell Transplantation Relapse: Prevention and Treatment
Even with the significant advances in blood and bone marrow stem cell transplant, relapse (also referred to as recurrent disease) remains the primary cause of treatment failure after both autologous and allogeneic transplantation. At the University of Chicago Medicine, we are dedicated to developing new treatments and strategies to monitor, prevent and treat relapse after transplant. And we are committed to bringing these therapies to our patients as soon as they are available.
Some of our current efforts include:
- Early identification of patients who are high risk for relapse in order to tailor therapy
- Modification of the conditioning regimen and the graft to enhance anti-tumor effects
- Development of novel early post-transplant preventative measures
- Close monitoring for recurrent disease to enable earlier treatment
- Development of new treatments, including cellular therapies, to treat recurrent disease
Internationally Recognized Expertise
At the University of Chicago Medicine, our expert physicians are also active researchers who continually explore new approaches to relapse prevention and treatment. For example,
Michael Bishop, MD, director of stem cell transplantation at the University of Chicago Medicine, is a leader of the International Post-Transplant Research Consortium. Members of this organization study the biological basis of relapse, assess interventions to prevent it, and evaluate new approaches to treat this complex condition.